Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Lymphoma: a Systematic Review and Meta-analysis

Overview

Journal Ann Hematol

Specialty Hematology

Date 2023 Jun 29

PMID 37382610

Authors

Yangyang Ding

Cheng Sun

Linhui Hu

Shudao Xiong

Zhimin Zhai

Affiliations

Soon will be listed here.

Abstract

Previous studies on the prognostic value of soluble programmed cell death ligand 1 (sPD-L1) in lymphoma patients have yielded inconsistent results. Here, we conducted a meta-analysis and systematic review to investigate the prognostic significance of sPD-L1 in lymphoma, especially in diffuse large B-cell lymphoma (DLBCL) and NK/T-cell lymphoma (NK/TCL). A total of 11 studies with 1185 patients were included in the meta-analysis, and the combined results indicated that high sPD-L1 levels were associated with worse overall survival (OS) (HR = 2.27, 95%CI: 1.70-3.04) and progression-free survival (PFS) (HR = 2.68, 95%CI: 1.92-3.75). Furthermore, subgroup analysis showed that sPD-L1 remained a significant prognostic factor for OS. The meta-analysis indicated that sPD-L1 may be a potential prognostic biomarker for lymphoma, especially in DLBCL and NK/TCL, and high sPD-L1 levels were associated with worse survival prognosis.

Citing Articles

Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis.

Lu H, Luo L, Mi J, Sun M, Wang H, Wang Z Front Oncol. 2025; 15:1506799.

PMID: 39959666 PMC: 11825807. DOI: 10.3389/fonc.2025.1506799.

Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications.

Chen L, Chao Y, Li W, Wu Z, Wang Q Biomark Res. 2024; 12(1):95.

PMID: 39218939 PMC: 11368031. DOI: 10.1186/s40364-024-00647-0.

References

Liu W, Liu J, Song Y, Zeng X, Wang X, Mi L . Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019; 12(1):115. PMC: 6862726. DOI: 10.1186/s13045-019-0785-7. View

Shankland K, Armitage J, Hancock B . Non-Hodgkin lymphoma. Lancet. 2012; 380(9844):848-57. DOI: 10.1016/S0140-6736(12)60605-9. View

Tilly H, Gomes Da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A . Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v116-25. DOI: 10.1093/annonc/mdv304. View

Constantinidou A, Alifieris C, Trafalis D . Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. Pharmacol Ther. 2018; 194:84-106. DOI: 10.1016/j.pharmthera.2018.09.008. View

Dermani F, Samadi P, Rahmani G, Kohlan A, Najafi R . PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol. 2018; 234(2):1313-1325. DOI: 10.1002/jcp.27172. View

Daassi D, Mahoney K, Freeman G . The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020; 20(4):209-215. DOI: 10.1038/s41577-019-0264-y. View

Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L . Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine. 2011; 56(2):231-8. DOI: 10.1016/j.cyto.2011.06.004. View

Frigola X, Inman B, Lohse C, Krco C, Cheville J, Thompson R . Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011; 17(7):1915-23. PMC: 3241002. DOI: 10.1158/1078-0432.CCR-10-0250. View

Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G . High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014; 28(12):2367-75. DOI: 10.1038/leu.2014.137. View

10.

Liao G, Zhao Z, Qian Y, Ling X, Chen S, Li X . Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2022; 11:774131. PMC: 8732757. DOI: 10.3389/fonc.2021.774131. View

11.

Xue J, Liu H, Meng G, Ding Z, Yan L, Yao S . Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Immunol Immunother. 2021; 71(7):1633-1644. PMC: 10992106. DOI: 10.1007/s00262-021-03103-2. View

12.

Ding Y, Sun C, Li J, Hu L, Li M, Liu J . The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis. Scand J Immunol. 2017; 86(5):361-367. DOI: 10.1111/sji.12596. View

13.

Rossille D, Azzaoui I, Feldman A, Maurer M, Laboure G, Parrens M . Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. Leukemia. 2016; 31(4):988-991. PMC: 5915627. DOI: 10.1038/leu.2016.385. View

14.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

15.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

16.

Wu X, Wang H, Deng J, Zheng X, Ling Y, Gong Y . Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis. Ann Hematol. 2019; 98(11):2485-2496. DOI: 10.1007/s00277-019-03774-z. View

17.

Wang Z, Liu W, Wang M, Li Y, Wang X, Yang E . Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis. Ann Hematol. 2021; 100(2):465-479. PMC: 7817569. DOI: 10.1007/s00277-020-04387-7. View

18.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

19.

Cho I, Lee H, Yoon S, Ryu K, Ko Y, Kim W . Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer. 2020; 20(1):120. PMC: 7020571. DOI: 10.1186/s12885-020-6612-2. View

20.

Fei Y, Yu J, Li Y, Li L, Zhou S, Zhang T . Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. J Cancer. 2020; 11(23):7001-7008. PMC: 7591999. DOI: 10.7150/jca.47816. View